Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Canada has acquired the Canadian rights to Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) from Takeda Pharmaceutical International.
Subscribe to our email newsletter
The two products have been approved by Health Canada and are indicated for the treatment of hypertension or high blood pressure.
Hypertension occurs when the blood pressure in the arteries is elevated and the heart has to work harder to pump blood through the blood vessels.
The company secured the rights of these products through a license, distribution and supply agreement with Takeda.
Valeant Canada Pharma Business Unit vice-president Richard Lajoie said: "The addition of these products to Valeant Canada’s portfolio will help us increase our presence in the cardiovascular field in Canada, while solidifying our position as a leader in the pharmaceutical industry."
The licensing of these products supports Valeant’s aim to meet patient treatment needs and to build on its current product offering to physicians in the cardio-metabolic field, which already includes Lodalis, Tiazac XC and Glumetza.
Takeda Canada president Mike Egli said: "Takeda Canada is committed to bringing new treatments to Canadians in the four vital disease areas of oncology, gastrointestinal disorders, respiratory diseases and metabolic disorders.
"The Edarbi family of products remains a priority for a variety of Takeda’s markets globally."